Central Nervous System Safety During Brief Analytic Treatment Interruption of Antiretroviral Therapy Within 4 Human Immunodeficiency Virus Remission Trials: An Observational Study in Acutely Treated People Living With Human Immunodeficiency Virus.
Joanna HellmuthCamilla MucciniDonn J ColbyEugène KroonMark de SouzaTrevor A CrowellPhillip ChanCarlo SacdalanJintana IntasanKhunthalee BenjapornpongSomporn TipsukSuwanna PuttamaswinNitiya ChomcheyVictor ValcourMichal SarneckiFrank TomakaShelly J KrebsBonnie M SlikeLinda L JagodzinskiNetsiri DumrongpisutikulNapapon SailasutaVishal SambojuNelson L MichaelMerlin L RobbSandhya VasanJintanat AnanworanichPraphan PhanuphakNittaya PhanuphakRobert PaulSerena SpudichPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
No adverse CNS effects were observed with brief, closely monitored ATI in participants with acutely treated HIV, except an MRS alteration in basal ganglia choline. Further studies are needed to assess CNS ATI safety in HIV remission trials, particularly for studies using higher thresholds to restart ART and longer ATI durations.